According to IBISWorld, the top five best-sellers set to lose patent protection in each of the next two years are:
Patent Expiring in 2011 Condition Company 2010 U.S. Sales Lipitor cholesterol Pfizer $5,329,000,000 Zyprexa antipsychotic Eli Lily $2,496,000,000 Levaquin antibiotics Johnson & Johnson $1,312,000,000 Concerta ADHD/ADD Johnson & Johnson $929,000,000 Protonix antacid Pfizer $690,000,000
Patent Expiring in 2012 Condition Company 2010 U.S. Sales Plavix anti-platelet Bristol-Myers Squibb /Sanofi-Aventis $6,154,000,000 Seroquel antipsychotic AstraZeneca $3,747,000,000 Singulair asthma Merck $3,224,000,000 Actos type 2 diabetes Takeda $3,351,000,000 Enbrel arthritis Amgen $3,304,000,000
via thestreet.com
No comments:
Post a Comment